AUPH - Better Buy: Amarin vs. Aurinia Pharmaceuticals
Investing in biotech stocks can feel like a rollercoaster ride. Positive clinical trial results, drug approvals, or lucrative partnership announcements can send stocks soaring. These stocks can just as easily get eviscerated on drug failures, regulatory setbacks, and patent challenges. To raise the stakes, look for biotechs that rely heavily on a single drug.
Investors in both Amarin (NASDAQ: AMRN) and Aurinia Pharmaceuticals (NASDAQ: AUPH) needed to buckle in tight to ride out the wild stock gyrations. In the past year, the two companies' stock prices have essentially swapped places between $6 and the mid-teens. Here we will explore what's behind these swings to see which provides a better investment.
Image Source: Getty Images.